Lysine-Binding Heterogeneity of Lp(a): Consequences for Fibrin Binding and Inhibition of Plasminogen Activation

C Bas Leerink; Pieter F C C M Duif; Joke A Gimpel; Wouter Kortlandt; Bonno N Bouma; Herman J M van Rijn

doi:10.1055/s-0038-1656346

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1992; 68(02): 185-188
DOI: 10.1055/s-0038-1656346

Original Article

Schattauer GmbH Stuttgart

Lysine-Binding Heterogeneity of Lp(a): Consequences for Fibrin Binding and Inhibition of Plasminogen Activation

C Bas Leerink

The Department of Clinical Chemistry, University Hospital Utrecht, Utrecht, The Netherlands

,

Pieter F C C M Duif

The Department of Clinical Chemistry, University Hospital Utrecht, Utrecht, The Netherlands

,

Joke A Gimpel

The Department of Clinical Chemistry, University Hospital Utrecht, Utrecht, The Netherlands

,

Wouter Kortlandt

The Department of Clinical Chemistry, University Hospital Utrecht, Utrecht, The Netherlands

,

Bonno N Bouma

¹The Department of Haematology, University Hospital Utrecht, Utrecht, The Netherlands

,

Herman J M van Rijn

The Department of Clinical Chemistry, University Hospital Utrecht, Utrecht, The Netherlands

› Author Affiliations

Abstract

PDF Download

Summary

Lipoprotein(a) [Lp(a)] is recognized as an independent risk factor for atherosclerosis. Lp(a) consists of a LDL-like moiety with an additional glycoprotein, apo(a), linked to apolipoprotein B-100. Apo(a) has a high homology with plasminogen (Pg). In vivo, Pg is activated on a fibrin surface by tissue Pg activator (tPA). We prepared Lp(a) from plasma by sequential ultracentrifugation followed by lysine-sepharose affinity chromatography. We found that a changing (donor dependent) fraction of the Lp(a) did not bind to lysine-sepharose. This fraction, designated Lp(a)lys–, was further purified using gel filtration. Bound Lp(a) [Lp(a)lys+] was eluted with 0.2 M EACA. Apo(a) isoforms in both fractions were identical. In contrast Lp(a)lys+ inhibited Pg activation by tPA in vitro (IC₅₀% 20 mg/1), whereas Lp(a)lys– did not. In addition Lp(a)lys– did not bind to CNBr-digested fibrinogen whereas Lp(a)lys+ did (K _d, _app = 0.2 nM). Therefore we conclude that a changing donor dependent fraction of human plasma Lp(a) does not inhibit Pg activation in vitro and does not bind to CNBr-digested fibrinogen.

PDF (1068 kb)

References

References
1 Scanu AM. Lipoprotein(a): a potential bridge between the fields of atherosclerosis and thrombosis. Arch Pathol Lab Med 1988; 112: 1045-1047
2 Fless GM, ZumMallen ME, Scanu AM. Physicochemical properties of apolipoprotein(a) and lipoprotein(a–) derived from the dissociation of human plasma lipoprotein(a). J Biol Chem 1988; 261: 8712-8718
3 McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330: 132-137
4 Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a): fibrin binding and plasminogen activation. Arteriosclerosis 1990; 10: 240-245
5 Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb Res 1990; 57: 155-162
6 Harpel PC, Gordon BR, Parker TS. Plasmin catalyses binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989; 86: 3847-3851
7 Leerink CB, Gimpel JA, Kortlandt W, Bouma BN, Van Rijn HJM. Kinetic analysis of lipoprotein(a) inhibition of plasminogen activation by tissue plasminogen activator in vitro. Fibrinolysis 1991; 5: 233-239
8 Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339: 303-305
9 Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 339: 301-303
10 Gonzalez-Gronow M, Edelberg JM, Pizzo SV. Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein(a) compete for the same site. Biochemistry 1989; 28: 2374-2378
11 Rouy D, Grailhe P, Nigon F, Chapman J, Anglés-Cano E. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. Arteriosclerosis Thromb 1991; 11: 629-638
12 Armstrong VW, Harrach B, Robenek H, Helmhold M, Walli AK, Seidel D. Heterogeneity of human lipoprotein Lp(a): cytochemical and biochemical studies on the interaction of two Lp(a) species with the LDL receptor. J Lipid Res 1990; 31: 429-441
13 Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a) lipoprotein concentrations in plasma. J Clin Invest 1987; 80: 458-465
14 Urano T, Sato de Serrano V, Gaffney PJ, Castellino FJ. Effectors of the activation of human (Glu¹⁾plasminogen by human tissue plasminogen activator. Biochemistry 1988; 27: 6522-6528
15 Hayes ML, Castellino FJ. Carbohydrate of the human plasminogen variants. J Biol Chem 1979; 254: 8768-8771
16 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. J Biol Chem 1982; 257: 2912-2919